Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to Gilead's Third Quarter 2025 Earnings Conference Call. My name is Rebecca, and I'll be today's host.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 669,001 | $74,259,142 | +1% | 1.61% |
| 2. | Polaris Capital Management Bernard Horn | 312,400 | $34,676,400 | -4% | 2.28% |
| 3. | Lee Munder Capital Group Lee Munder | 17,726 | $1,967,586 | -1% | 0.12% |
| 4. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 9,878 | $1,096,458 | -11% | 0.51% |
| 5. | Ayrshire Capital Management John Nevin Jr. | 5,400 | $599,400 | 0.28% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | $999,150.00 | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | $430,493.00 | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | $439,955.00 | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | $335,974.40 | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | $158,064.64 | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $118.82 | 2,022 | $240,258.69 | 581,203 | 2025-10-28 | Filing | |
| $119.54 | 7,978 | $953,666.98 | 583,225 | 2025-10-28 | Filing | |
| $118.08 | 2,500 | $295,200.00 | 157,055 | 2025-10-15 | Filing | |
| $118.08 | 3,000 | $354,240.00 | 110,193 | 2025-10-15 | Filing | |
| $112.42 | 1,961 | $220,454.25 | 591,203 | 2025-09-29 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,412,598 | $494,034,472 | 0.43% | |
| 2. | 3,845,379 | $426,837,069 | 1.45% | |
| 3. | 3,801,951 | $422,016,561 | 0.61% | |
| 4. | 3,590,745 | $398,572,695 | 1% | |
| 5. | 3,489,062 | $387,285,882 | 0.53% |
News See All
RBC Warns Gilead (GILD) Faces Risk from Trump's Price Cut Target
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies. On October 1, RBC analysts stated that Gilead Sciences, Inc.
11 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies
Renaissance Technologies has not had the best of runs in an action-filled year that has seen equity markets rally to record highs.
RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical stocks to buy now. RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences, Inc.
Gilead Foundation Commits Over $6.5M in New Grant Funding to Support STEM Education Pathways
Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued stocks to buy and hold for 5 years.
10 Most Undervalued Stocks to Buy and Hold for 5 Years
On September 24, Richard Fisher, former Dallas Fed President & Jefferies senior advisor, joined 'Closing Bell' on CNBC to discuss how valuations are very strong and concentrated.
12 Best Medical Stocks to Buy Now
On September 26, Geoff Meacham, Managing Director of Citi Research, appeared on CNBC’s “Closing Bell Overtime” to talk about President Trump’s plan to impose a 100% tariff on “all any branded...
What Do Analysts Think About Gilead Sciences (GILD)?
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best large cap value stocks to buy now. On September 22, Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences, Inc.
11 Best Large Cap Value Stocks to Buy Now
On September 26, Jeremy Siegel, Wharton professor emeritus and WisdomTree senior economist, appeared on CNBC's ‘Closing Bell’ to talk about the latest PCE report, whether the Fed should deemphasize...
Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum
Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the most undervalued NASDAQ stocks to buy now. Citing momentum in Gilead Sciences, Inc.
Hedge Fund Resource Center Billionaire Hedge Funds
